Short Interest in Aptose Biosciences Inc. (NASDAQ:APTO) Expands By 1,012.9%

Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) was the target of a significant growth in short interest in the month of January. As of January 15th, there was short interest totalling 2,090,000 shares, a growth of 1,012.9% from the December 31st total of 187,800 shares. Currently, 3.7% of the shares of the company are sold short. Based on an average daily volume of 6,360,000 shares, the short-interest ratio is currently 0.3 days.

Aptose Biosciences Price Performance

Shares of APTO traded down $0.02 during trading hours on Tuesday, hitting $0.19. The stock had a trading volume of 511,550 shares, compared to its average volume of 782,672. Aptose Biosciences has a 12 month low of $0.13 and a 12 month high of $2.20. The stock has a fifty day moving average price of $0.22 and a 200 day moving average price of $0.36. The firm has a market capitalization of $11.25 million, a PE ratio of -0.06 and a beta of 0.87.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. StockNews.com began coverage on Aptose Biosciences in a report on Friday. They issued a “hold” rating on the stock. HC Wainwright reiterated a “buy” rating and set a $2.00 price target on shares of Aptose Biosciences in a report on Friday, January 10th.

Institutional Investors Weigh In On Aptose Biosciences

An institutional investor recently raised its position in Aptose Biosciences stock. Sigma Planning Corp raised its position in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 71.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 401,750 shares of the biotechnology company’s stock after acquiring an additional 167,282 shares during the period. Sigma Planning Corp owned approximately 2.22% of Aptose Biosciences worth $165,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 26.62% of the company’s stock.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.